Gallbladder neoplasm
MONDO:0021253A neoplasm (disease) that involves the gall bladder.
Also known as: gall bladder neoplasm, gall bladder neoplasm (disease), gall bladder tumor, gall bladder tumour, gallbladder tumor, gallbladder tumour, neoplasm of gall bladder, neoplasm of gallbladder
1573 clinical trials for this condition and its sub-types, 63 tagged with Gallbladder neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Gallbladder neoplasm
-
Gallbladder cancer 75 trials · 109 incl. sub-types
5 sub-types
- Gallbladder carcinoma 41 trials · 49 incl. sub-types Sub-types →
- Gallbladder melanoma 1 trial
- Gallbladder lymphoma 0 trials
- Gallbladder sarcoma 0 trials Sub-types →
- Neurofibroma of gallbladder 0 trials
-
Benign neoplasm of gallbladder 0 trials
2 sub-types
- Gallbladder leiomyoma 0 trials
- Gallbladder lipoma 0 trials
-
Gallbladder adenoma 0 trials
-
Gallbladder neuroendocrine neoplasm 0 trials
2 sub-types
-
Gallbladder papillary neoplasm 0 trials
1 sub-type
Most studied deeper sub-types
-
New drug combo tested for tough bile duct cancers
Disease control Stopped earlyThis study tested a new drug called LSTA1 added to standard treatment for people with advanced bile duct or gallbladder cancer. The goal was to see if the combination is safe and works better than standard treatment alone. The trial was stopped early, and results are not yet avai…
Phase 2 • Sponsor: Lisata Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New cancer drug trial halted early – what we know
Disease control Stopped earlyThis study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental combo shows promise for tough bile duct cancer
Disease control Stopped earlyThis study tested whether adding an experimental drug called CPI-613 (devimistat) to standard chemotherapy (gemcitabine plus cisplatin) could help people with advanced biliary tract cancer that cannot be removed by surgery. The trial had two parts: first, finding the safest dose …
Phase 1/2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Cancer gene hunt: could tumor maps guide better GI cancer treatment?
Knowledge-focused Stopped earlyThis study looked at genetic mutations in tumors from 565 people with advanced gastrointestinal cancers, including liver, bile duct, gallbladder, pancreas, esophagus, and stomach cancers. The goal was to see how often these mutations could be targeted by existing drugs and to tra…
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC